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Abstract
Background:  The gene encoding apolipoprotein E (APOE) has been proposed as a candidate gene
for vascular complications in Type I diabetes. This study aimed to investigate the influence of three-
allelic variations in the APOE gene for the development of diabetic retinopathy and nephropathy.
Results:  Neither APOE alleles frequencies or APOE genotypes frequencies differed between Type
I diabetic groups either with or without nephropathy. Similar results were found for patients with
and without diabetic retinopathy.
Conclusions:    APOE gene polymorphism does not determine genetic susceptibility for the
development of diabetic retinopathy in Type I diabetes patients. Association between APOE gene
polymorphism and diabetic nephropathy may be weak or moderate, but not strong.
Background
Familial and epidemiological studies have indicated that
there is a strong genetic component in the aetiology of di-
abetic nephropathy in Type I diabetes patients [1,2].
Apolipoprotein E (apoE) was discovered as a plasma pro-
tein involved in the metabolism of lipoproteins. Recent-
ly, the apolipoprotein E (APOE) gene has been suggested
to be a risk factor for the development of micro- and
macrovascular complications in diabetic patients.
The APOE gene is polymorphic. There are three common
alleles, E2, E3, and E4, which code for three major iso-
forms, resulting in six common genotypes [3,4]. Individ-
uals with apoE2 have higher triglyceride levels and are
associated with lower cholesterol compared to individu-
als with apoE3. Individuals with apoE4 often have ele-
vated plasma cholesterol levels. There is an increased
prevalence of cardiovascular disease and particularly
Alzheimer's disease [5,6,7].
Apolipoprotein E polymorphism may influence the me-
tabolism of lipoproteins in diabetic patients. Several re-
cent studies have suggested that this polymorphism may
be associated with a genetic predisposition for diabetic
nephropathy [8,9,10,11]. Thus, APOE is an important
candidate gene for the development of microvascular
complications in Type I diabetes patients.
The aim of this study was to investigate the influence of
APOE gene polymorphism in the development of diabet-
ic nephropathy and retinopathy in Type I diabetes pa-
tients.
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Materials and Methods
Patients
In this study, all patients were Russians with unrelated
Type I diabetes. All diabetic patients for the case-control
study were recruited from St.Petersburg Diabetological
Centres and had participated in the program "Diabetes
mellitus" (which included monitoring of trends and ex-
aminations of the determinants of vascular complica-
tions in Type I diabetes) carried out in St. Petersburg,
Russia since 1997.
The diabetic patients included in this study satisfied the
World Health Organization criteria for diabetes mellitus
[12]. Glycated haemoglobin (HbAlc) was measured by
ion exchange chromatography [13]. At entry the patients
had HbAlc levels of 5.7 to 16.8%.
The Type I diabetes groups consisted of 74 subjects with
nephropathy and 92 subjects without. The study covered
76 Type I diabetes patients with diabetic retinopathy and
96 patients without. Some subjects had more than one
type of diabetic complication, and consequently were an-
alysed in more than one group.
For Type I diabetes patients, all the information was ex-
amined for evidence of nondiabetic renal disease. Then
questionnaires, medical records, and measurements of
albumin excretion were used to determine whether they
had diabetic nephropathy. Those patients were consid-
ered to have diabetic nephropathy if they were receiving
treatment for renal disease and either suffered from per-
sisting proteinuria, or had persisting high albuminuria.
Urinary albumin excretion was measured by nephelom-
etry [14]. Nephropathy was defined as a persistent uri-
nary albumin excretion of more than 20 µg/min, or 30
mg/24 h in two out of three consecutive urinalyses. Indi-
viduals with no history of nephropathy and no albumin
excretion were considered free of nephropathy.
Fundus ophthalmoscopy and angiofluorography were
used to diagnose retinopathy. The diabetic retinopathy
group consisted of those showing retinal change, while
Type I diabetes control group were those who showed no
signs of retinopathy.
DNA genotyping
Blood was collected from each individual and stored in
ethylenediaminetetraacetic acid (EDTA) tubes at -20°C.
Genomic DNA was obtained from lysed white blood cells
by phenol-chloroform extraction. The APOE gene poly-
morphism was detected by polymerase chain reaction
(PCR). APOE genotyping was performed by the method
of Hixson and Vernier [15] using a modified version de-
scribed by Skobeleva et al. [16].
The sequence of the sense oligonucleotide primer was 5'-
AGATGCGGGCACGGCTGTTCAAGGA-3', and the anti-
sense primer was 5'-CCCTCGCGAGCCCCGGCCTGGTA-
CAC-3' [16]. Each amplification reaction contained 50
mM KCl, 10 mM tris-HCl pH 8.4, 1.5 mM MgCl2, 0.25
µM of each primer, 200 µM dNTP, 10% DMSO, 0.1 µg
DNA and 1 U Tag polymerase in a final volume of 20 µl.
After denaturation step at 95°C for 5 minutes followed by
30 cycle of denaturation at 92°C (1 min), annealing at
64°C (1 min), extension at 72°C (1.5 min) and a final ex-
tension at 72°C (5 min) using a MiniCycler (MJ Re-
search, Watertown, MA, USA). Genotypes were
determined by Hin61 (Fermentas, Vilnius, Lithuania) di-
gestion of a 244-base pair PCR-amplified fragment span-
ning the two polymorphic sites. The digested DNA
fragments were separated using migration on 12% poly-
acrylamide gels and visualized under UV illumination af-
Table 1: Clinical characteristics by study groups
Type I diabetes subjects 
with nephropathy
Type I diabetes subjects 
without nephropathy
Type I diabetes subjects 
with retinopathy
Type I diabetes subjects 
without retinopathy
(DN+) (DN-) (DR+) (DR-)
Total subjects 74 92 76 96
Age (years) 25.1 ± 11.9 20.8 ± 8.7 29.8 ± 10.1 22.9 ± 9.1
Sex
(male/female) 40/34 40/52 34/42 50/46
Diabetes
duration 14.8 ± 8.8 10.9 ± 4.3 17.4 ± 8.6 11.2 ± 3.1
(years)
Diabetes onset
(years) 11.1 ± 6.2 10.3 ± 6.8 12.2 ± 8.1 11.5 ± 5.2
HbA1c(%) 10.5 ± 2.2 9.8 ± 1.9 10.6 ± 1.7 9.9 ± 1.7
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ter ethidium bromide staining [16]. The codominant
alleles E2, E3, and E4 determine the six APOE geno-
types.
Statistical testing
All data are presented as means ± SD. Groups were com-
pared using the Student's t test for comparison of two
groups for quantitative variables. Allele frequency
among control subjects and case subjects were compared
using standard Χ 2 tests. The difference in genotype fre-
quencies between the groups was tested by Fisher's exact
test. A value of P < 0.05 was considered significant.
Results
Clinical characteristics by study group are shown in Ta-
ble 1. No significant difference was seen between groups
with vascular complications (nephropathy and retinopa-
thy) and those without, no matter the age, diabetes dura-
tion, age at diabetes onset, and mean HbAlc.
Table 2: Distributionof APOE genotypes and alleles in the case-control association study
Type I diabetes subjects 
with nephropathy
Type I diabetes subjects 
without nephropathy
P value Type I diabetes subjects 
with retinopathy
Type I diabetes subjects 
without retinopathy
P Value
(DN+) (DN-) (DR+) (DR-)
n (%) n (%) n (%) n (%)
m/f (%/%) m/f (%/%) m/f (%/%) m/f (%/%)
74 (100) 92(100) 76 (100) 96(100)
Total subjects 40/34 40/52 34/42 50/46
(54.0/46.0) (43.5/56.5) (44.7/55.3) (52.1/47.9)
2(2.2) 1(1.0)
E2E2 00 / 2 N S 00 / 1 N S
(0/3.8) (0/2.2)
48(64.9) 54(58.7) 45(59.2) 61(63.6)
E3E3 25/23 27/27 NS 21/24 33/28 NS
(62.5/67.6) (67.5/51.9) (61.8/57.1) (66.9/60.9)
1(1.0)
E4E4 0 0 NS 0 0/1 NS
(0/2.2)
13(17.6) 20(21.7) 18(23.7) 16(16.7)
E2E3 8/5 5/15 NS 9/9 6/10 NS
(20.0/14.7) (12.5/28.8) (26.4/21.4) (12.0/21.7)
3(4.0) 3(3.9) 1(1.0)
E2E4 0/3 0 NS 0/3 1/0 NS
(0/8.9) (0/7.2) (2.0/0)
10(13.5) 16(17.4) 10(13.2) 16(16.7)
E3E4 7/3 8/8 NS 4/6 10/6 NS
(17.5/8.8) (20.0/15.5) (11.8/14.3) (20.0/13.0)
16(10.8) 24(13.0) 21(13.8) 19(9.9)
E2 8/8 5/19 NS 9/12 7/12 NS
(10.0/11.8) (6.3/18.3) (13.2/14/3) (7.0/13.0)
119(80.4) 144(78.3) 118(77.6) 154(80.2)
E3 65/54 67/77 NS 55/63 82/72 NS
(81.3/79.4) (83.7/74.0) (80.9/75.0) (82.0/78.3)
13(8.8) 16(8.7) 13(8.6) 19(9.9)
E4 7/6 8/8 NS 4/9 11/8 NS
(8.7/8.8) (10.0/7.7) (5.9/10.7) (11.0/8.7)
Total chromosomes 148 (100) 184(100) 152(100) 192(100)
80/68 40/104 68/84 100/92
(54.1/45.9) (43.5/56.5) (44.7/55.3) (52.1/47.9)
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The frequency of each genotype in each group conformed
to the Hardy -Weinberg equilibrium.
The distribution of the APOE genotypes is shown in Ta-
ble 2. There was no significant difference in APOE geno-
type and allele frequency between nephropathic and
normoalbuminuric diabetic patients. In this study, no as-
sociation was found between diabetic retinopathy and
APOE polymorphisms. APOE allele frequencies for
males and females were similar within groups and in dif-
ferent groups.
Discussion
Diabetic nephropathy and diabetic retinopathy are the
two most important microangiopathic complications in
Type I diabetic patients. Many of the environmental fac-
tors that influence the risk of vascular disease are known,
but genetic components of the risk for diabetic microan-
giopathy are poorly understood. Several candidate genes
have been investigated to elucidate the genetic factors re-
sponsible for vascular complications. The most impor-
tant of these are the aldose reductase gene (ALR2) [17],
the insertion/deletion (I/D) polymorphism of the angi-
otensin I – converting enzyme (ACE) gene [18,19],
C825T polymorphism of the gene encoding the beta-3
subunit of geterotrimeric G-proteins (GNB3) [20,21,22],
and C677T polymorphism of the methylenetetrahydro-
folate reductase gene (MTHFR) [23].
The genetic polymorphism of apolipoprotein E is associ-
ated with lipid abnormalities. Eto et al. [9] suggested
that lipid abnormalities may contribute to the develop-
ment and progression of kidney disease, including dia-
betic nephropathy. The E2 allele frequency was
significantly higher in Type II diabetes patients with ne-
phropathy (7.2%) and with renal failure (9.7%) than in
diabetic patients without nephropathy (2.6%) [9]. Apoli-
poprotein E polymorphism is associated with the pro-
gression of diabetic nephropathy. Presence of the
apolipoprotein E4 allele is a protective factor, and other
alleles entail risk factors [24].
The genes responsible for genetic predisposition to vas-
cular complications are still unknown, and little is
known about the molecular basis of these complications.
The influence of the APOE gene polymorphism to the de-
velopment of diabetic microangiopathy is uncertain.
Chowdhury et al. [10] and Araki et al. [11] demonstrated
an association between the presence of the APOE E2 al-
lele and diabetic nephropathy in Caucasian patients with
Type I diabetes, although some investigators do not sup-
port this association [25,26].
This study elucidated the role of APOE gene polymor-
phism in the predisposition to diabetic vascular compli-
cations. No association ofAPOE gene polymorphism
with diabetic nephropathy was demonstrated. This re-
sult for diabetic nephropathy confirms the findings of
Tarnow et al. [25] and Onuma et al. [26]. It should be
mentioned that sample sizes in [10,11] were larger than
in this study. With increased sample size comes the pos-
sibility to demonstrate an association. But the larger the
necessary and sufficient minimal sample size, the weaker
the association demonstrated.
We also analysed the association of the APOE gene poly-
morphism with diabetic retinopathy in the present
study. No significant differences were found between
groups with and without this vascular complication. A
similar result has been shown by Tarnow et al. [25] for
diabetic retinopathy.
Conclusions
The present study found no evidence for a role of the
APOE gene polymorphism in genetic susceptibility for
the development of diabetic retinopathy in Type I diabe-
tes patients. Association between APOE gene polymor-
phism and diabetic nephropathy may be weak or
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